{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:36:13Z","timestamp":1764322573397,"version":"3.46.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orthop\u00e4die"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00132-025-04713-9","type":"journal-article","created":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:10:38Z","timestamp":1760965838000},"page":"953-957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osteoanabole Therapieoptionen","Osteo-anabolic treatment strategies"],"prefix":"10.1007","volume":"54","author":[{"given":"Ulla","family":"Stumpf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"key":"4713_CR1","unstructured":"AWMF S3 Leitlinie Prophylaxe, Diagnostik und Therapie der Osteoporose bei postmenopausalen Frauen und bei M\u00e4nnern ab dem 50.Lebensjahr (2023) AWMF Registernummer: 183-001, https:\/\/www.awmf.org"},{"key":"4713_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/en.2015-1726","volume":"157","author":"G Hattersley","year":"2016","unstructured":"Hattersley\u00a0G, Dean\u00a0T, Corbin\u00a0BA, Bahar\u00a0H, Gardella\u00a0TJ (2016) Binding Selectivity of Abaloparatide for PTH-Type-1-Receptor Conformations and Effects on Downstream Signaling. Endocrinology 157:141\u2013149. https:\/\/doi.org\/10.1210\/en.2015-1726","journal-title":"Endocrinology"},{"key":"4713_CR3","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","volume":"5","author":"S Khosla","year":"2017","unstructured":"Khosla\u00a0S, Hofbauer\u00a0LC (2017) Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol 5:898\u2013907. https:\/\/doi.org\/10.1016\/S2213-8587(17)30188-2","journal-title":"Lancet Diabetes Endocrinol"},{"key":"4713_CR4","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer\u00a0RM, Arnaud\u00a0CD, Zanchetta\u00a0JR, Prince\u00a0R, Gaich\u00a0GA, Reginster\u00a0J\u2011Y, Hodsman\u00a0AB, Eriksen\u00a0EF, Ish-Shalom\u00a0S, Genant\u00a0HK, Wang\u00a0O, Mellstr\u00f6m\u00a0D, Oefjord\u00a0ES, Marcinowska-Suchowierska\u00a0E, Salmi\u00a0J, Mulder\u00a0H, Halse\u00a0J, Sawicki\u00a0AZ, Mitlak\u00a0BH (2001) Effect of Parathyroid Hormone (1\u201334) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis. N\u00a0Engl J Med 344:1434\u20131441. https:\/\/doi.org\/10.1056\/NEJM200105103441904","journal-title":"N Engl J Med"},{"key":"4713_CR5","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","volume":"391","author":"DL Kendler","year":"2018","unstructured":"Kendler\u00a0DL, Marin\u00a0F, Zerbini\u00a0CAF, Russo\u00a0LA, Greenspan\u00a0SL, Zikan\u00a0V, Bagur\u00a0A, Malouf-Sierra\u00a0J, Lakatos\u00a0P, Fahrleitner-Pammer\u00a0A, Lespessailles\u00a0E, Minisola\u00a0S, Body\u00a0JJ, Geusens\u00a0P, M\u00f6ricke\u00a0R, L\u00f3pez-Romero\u00a0P (2018) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a\u00a0multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 391:230\u2013240. https:\/\/doi.org\/10.1016\/S0140-6736(17)32137-2","journal-title":"Lancet"},{"key":"4713_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2023045480","volume":"40","author":"N Mittal","year":"2023","unstructured":"Mittal\u00a0N, Sharma\u00a0G, Katare\u00a0OP, Bhadada\u00a0SK (2023) A Narrative Review on Non-Invasive Drug Delivery of Teriparatide: A\u00a0Ray of Hope. Crit Rev Ther Drug Carrier Syst 40:117\u2013140. https:\/\/doi.org\/10.1615\/CritRevTherDrugCarrierSyst.2023045480","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"4713_CR7","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1210\/jc.2009-0358","volume":"95","author":"F Cosman","year":"2010","unstructured":"Cosman\u00a0F, Lane\u00a0NE, Bolognese\u00a0MA, Zanchetta\u00a0JR, Garcia-Hernandez\u00a0PA, Sees\u00a0K, Matriano\u00a0JA, Gaumer\u00a0K, Daddona\u00a0PE (2010) Effect of Transdermal Teriparatide Administration on Bone Mineral Density in Postmenopausal Women. J\u00a0Clin Endocrinol Metab 95:151\u2013158. https:\/\/doi.org\/10.1210\/jc.2009-0358","journal-title":"J Clin Endocrinol Metab"},{"key":"4713_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/bcp.70064","author":"JT Myers","year":"2025","unstructured":"Myers\u00a0JT, Yamaguchi\u00a0A, Vo\u00a0AT, Dasari\u00a0A, Battiwala\u00a0A, Patel\u00a0N, Fung\u00a0LC, Gonen\u00a0OM, Imran\u00a0M, Van Dam\u00a0J, Hashim\u00a0MA, Dhalla\u00a0AK, Bilezikian\u00a0JP (2025) An oral robotic pill reliably and safely delivers teriparatide with high bioavailability in healthy volunteers: A\u00a0phase\u00a01\u00a0study. Br J Clin Pharmacol. https:\/\/doi.org\/10.1002\/bcp.70064","journal-title":"Br J Clin Pharmacol"},{"key":"4713_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11657-019-0564-7","volume":"14","author":"EV McCloskey","year":"2019","unstructured":"McCloskey\u00a0EV, Fitzpatrick\u00a0LA, Hu\u00a0M\u2011Y, Williams\u00a0G, Kanis\u00a0JA (2019) Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a\u00a0subset of postmenopausal women at increased risk of fracture by FRAX probability. Arch Osteoporos 14:15. https:\/\/doi.org\/10.1007\/s11657-019-0564-7","journal-title":"Arch Osteoporos"},{"key":"4713_CR10","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ajhp\/zxy022","volume":"76","author":"A Sleeman","year":"2019","unstructured":"Sleeman\u00a0A, Clements\u00a0JN (2019) Abaloparatide: A\u00a0new pharmacological option for osteoporosis. Am J Heal Pharm 76:130\u2013135. https:\/\/doi.org\/10.1093\/ajhp\/zxy022","journal-title":"Am J Heal Pharm"},{"key":"4713_CR11","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00198-017-4304-9","volume":"29","author":"JP Bilezikian","year":"2018","unstructured":"Bilezikian\u00a0JP, Hattersley\u00a0G, Fitzpatrick\u00a0LA, Harris\u00a0AG, Shevroja\u00a0E, Banks\u00a0K, Leder\u00a0BZ, Zanchetta\u00a0JR, Hans\u00a0D (2018) Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a\u00a024-week randomized clinical trial. Osteoporos Int 29:323\u2013328. https:\/\/doi.org\/10.1007\/s00198-017-4304-9","journal-title":"Osteoporos Int"},{"key":"4713_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1210\/jc.2014-3718","volume":"100","author":"BZ Leder","year":"2015","unstructured":"Leder\u00a0BZ, O\u2019Dea\u00a0LSL, Zanchetta\u00a0JR, Kumar\u00a0P, Banks\u00a0K, McKay\u00a0K, Lyttle\u00a0CR, Hattersley\u00a0G (2015) Effects of Abaloparatide, a\u00a0Human Parathyroid Hormone-Related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis. J\u00a0Clin Endocrinol Metab 100:697\u2013706. https:\/\/doi.org\/10.1210\/jc.2014-3718","journal-title":"J Clin Endocrinol Metab"},{"key":"4713_CR13","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller\u00a0PD, Hattersley\u00a0G, Riis\u00a0BJ, Williams\u00a0GC, Lau\u00a0E, Russo\u00a0LA, Alexandersen\u00a0P, Zerbini\u00a0CAF, Hu\u00a0M, Harris\u00a0AG, Fitzpatrick\u00a0LA, Cosman\u00a0F, Christiansen\u00a0C (2016) Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis. JAMA 316:722. https:\/\/doi.org\/10.1001\/jama.2016.11136","journal-title":"JAMA"},{"key":"4713_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.eprac.2024.10.017","volume":"31","author":"L Tabatabai","year":"2025","unstructured":"Tabatabai\u00a0L, Cosman\u00a0F, Curtis\u00a0JR, DeSapri\u00a0KT, LaBaume\u00a0CT, Reginster\u00a0J\u2011Y, Rizzoli\u00a0R, Cortet\u00a0B, Wang\u00a0Y, Chiodo\u00a0J, Mitlak\u00a0BH (2025) Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a\u00a0Real-World Retrospective Analysis. Endocr Pract 31:159\u2013168. https:\/\/doi.org\/10.1016\/j.eprac.2024.10.017","journal-title":"Endocr Pract"},{"key":"4713_CR15","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/jbmr.4764","volume":"38","author":"FM Cosman","year":"2020","unstructured":"Cosman\u00a0FM, Hans\u00a0DP, Shevroja\u00a0EP, Wang\u00a0YP, Mitlak\u00a0BM (2020) Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend. J\u00a0Bone Miner Res 38:464\u2013470. https:\/\/doi.org\/10.1002\/jbmr.4764","journal-title":"J Bone Miner Res"},{"key":"4713_CR16","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1002\/jbmr.3848","volume":"34","author":"BZ Leder","year":"2019","unstructured":"Leder\u00a0BZ, Zapalowski\u00a0C, Hu\u00a0M\u2011Y, Hattersley\u00a0G, Lane\u00a0NE, Singer\u00a0AJ, Dore\u00a0RK (2019) Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase\u00a03 ACTIVExtend Trial. J\u00a0Bone Miner Res 34:2213\u20132219. https:\/\/doi.org\/10.1002\/jbmr.3848","journal-title":"J Bone Miner Res"},{"key":"4713_CR17","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone\u00a0HG, Cosman\u00a0F, Miller\u00a0PD, Williams\u00a0GC, Hattersley\u00a0G, Hu\u00a0M, Fitzpatrick\u00a0LA, Mitlak\u00a0B, Papapoulos\u00a0S, Rizzoli\u00a0R, Dore\u00a0RK, Bilezikian\u00a0JP, Saag\u00a0KG (2018) ACTIVExtend: 24\u00a0Months of Alendronate After 18\u00a0Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis. J\u00a0Clin Endocrinol Metab 103:2949\u20132957. https:\/\/doi.org\/10.1210\/jc.2018-00163","journal-title":"J Clin Endocrinol Metab"},{"key":"4713_CR18","doi-asserted-by":"publisher","unstructured":"Dhaliwal R, Hans D, Hattersley G, Mitlak B, Fitzpatrick LA, Wang Y, Schwartz A V, Miller PD, Josse RG (2020) Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study. JBMR Plus 4. https:\/\/doi.org\/10.1002\/jbm4.10346","DOI":"10.1002\/jbm4.10346"},{"key":"4713_CR19","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1210\/clinem\/dgaa450","volume":"105","author":"F Cosman","year":"2020","unstructured":"Cosman\u00a0F, Peterson\u00a0LR, Towler\u00a0DA, Mitlak\u00a0B, Wang\u00a0Y, Cummings\u00a0SR (2020) Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase\u00a03 Trial. J\u00a0Clin Endocrinol Metab 105:3384\u20133395. https:\/\/doi.org\/10.1210\/clinem\/dgaa450","journal-title":"J Clin Endocrinol Metab"},{"key":"4713_CR20","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00198-022-06413-y","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman\u00a0F, Cooper\u00a0C, Wang\u00a0Y, Mitlak\u00a0B, Varughese\u00a0S, Williams\u00a0SA (2022) Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: A\u00a0US administrative claims database study. Osteoporos Int 33:1703\u20131714. https:\/\/doi.org\/10.1007\/s00198-022-06413-y","journal-title":"Osteoporos Int"},{"key":"4713_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s40261-021-01008-7","volume":"41","author":"PD Miller","year":"2021","unstructured":"Miller\u00a0PD, Troy\u00a0S, Weiss\u00a0RJ, Annett\u00a0M, Schense\u00a0J, Williams\u00a0SA, Mitlak\u00a0B (2021) Phase\u00a01b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density. Clin Drug Investig 41:277\u2013285. https:\/\/doi.org\/10.1007\/s40261-021-01008-7","journal-title":"Clin Drug Investig"},{"key":"4713_CR22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.bone.2010.09.009","volume":"48","author":"X Tian","year":"2011","unstructured":"Tian\u00a0X, Jee\u00a0WSS, Li\u00a0X, Paszty\u00a0C, Ke\u00a0HZ (2011) Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a\u00a0hindlimb-immobilization rat model. Bone 48:197\u2013201. https:\/\/doi.org\/10.1016\/j.bone.2010.09.009","journal-title":"Bone"},{"key":"4713_CR23","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman\u00a0F, Crittenden\u00a0DB, Adachi\u00a0JD, Binkley\u00a0N, Czerwinski\u00a0E, Ferrari\u00a0S, Hofbauer\u00a0LC, Lau\u00a0E, Lewiecki\u00a0EM, Miyauchi\u00a0A, Zerbini\u00a0CAF, Milmont\u00a0CE, Chen\u00a0L, Maddox\u00a0J, Meisner\u00a0PD, Libanati\u00a0C, Grauer\u00a0A (2016) Romosozumab Treatment in Postmenopausal Women with Osteoporosis. N\u00a0Engl J Med 375:1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948","journal-title":"N Engl J Med"},{"key":"4713_CR24","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag\u00a0KG, Petersen\u00a0J, Brandi\u00a0ML, Karaplis\u00a0AC, Lorentzon\u00a0M, Thomas\u00a0T, Maddox\u00a0J, Fan\u00a0M, Meisner\u00a0PD, Grauer\u00a0A (2017) Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N\u00a0Engl J Med 377:1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMoa1708322","journal-title":"N Engl J Med"}],"container-title":["Die Orthop\u00e4die"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00132-025-04713-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00132-025-04713-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00132-025-04713-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T09:31:53Z","timestamp":1764322313000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00132-025-04713-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":24,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["4713"],"URL":"https:\/\/doi.org\/10.1007\/s00132-025-04713-9","relation":{},"ISSN":["2731-7145","2731-7153"],"issn-type":[{"type":"print","value":"2731-7145"},{"type":"electronic","value":"2731-7153"}],"subject":[],"published":{"date-parts":[[2025,10,20]]},"assertion":[{"value":"7 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"U.\u00a0Stumpf: Durchf\u00fchrung klinischer Studien, Vortr\u00e4ge\u2011\/Beratert\u00e4tigkeit f\u00fcr Amgen, UCB, Eli Lilly, Theramex. A.\u00a0Kurth: Im Bezug zu den Inhalten des Artikels liegen folgende Interessenkonflikte vor: Amgen, Stada, UCB, Theramex.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Die in dieser \u00dcbersichtsarbeit dargestellten pr\u00e4klinischen sowie klinischen Studien sind im Einklang mit der Deklaration von Helsinki erfolgt. Zu allen Studien lag ein positives Ethikvotum vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}